Glenmark Pharmaceuticals has uploaded the transcript of its earnings call for the fourth quarter and year ended March 31, 2026. The conference call was held on Monday, June 01, 2026, and the transcript is now accessible on the company's website. This disclosure was made pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Earnings Call Transcript

The management discussed the company's performance for Q4 and the full fiscal year FY26 during the call. The transcript document provides a detailed record of the proceedings.

Regulatory Compliance

The submission confirms the availability of the transcript on the company's website. The communication was addressed to the National Stock Exchange of India Limited and BSE Limited, providing the necessary reference numbers and ISIN details for the scrip. The filing was submitted by Rashmi Khandelwal, Company Secretary & Compliance Officer.

Glenmark Pharmaceuticals has outlined an ambitious multi-pronged growth strategy for FY27, anchored by strong US business recovery, respiratory portfolio expansion, and key regulatory milestones in dermatology and oncology. The company has set revenue goals of ₹17,000 Cr to ₹18,000 Cr for FY27, targeting an EBITDA margin of 21% to 22%, with growth investments focused on India and emerging markets.

FY27 Financial Targets and Analyst View

Glenmark Pharmaceuticals has provided clear financial guidance for FY27, underpinned by a broad pipeline of product launches and operational discipline. HSBC has maintained a Buy rating on the company with a target price of ₹2,575, citing in-line Q4 revenue led by strong Europe performance and an expected recovery in US sales. The brokerage highlighted Fluticasone MDI 44 (gFloVent), respiratory products, and Monroe plant supplies as key drivers of the anticipated US sales rebound. The following table outlines the key financial targets and analyst parameters:

US Business and Respiratory Portfolio Expansion

Glenmark Pharmaceuticals has identified the US business as a significant growth engine for FY27, with Fluticasone MDI 44 and other respiratory launches expected to drive meaningful revenue contribution. The company also anticipates growth from Ryaltris and its innovative oncology products. Glenmark aims to maintain net working capital under 115 to 120 days, which it considers a leading industry standard, while continuing to invest in research and development at 7% to 8% of sales. The company also carries an income deferment of USD 70 million annually, recognised at USD 17.50 million each quarter.

Winlevi® Secures EU Approval

A significant regulatory milestone has been achieved with Winlevi® receiving approval from the European Union. The company has planned a commercial launch of the product in FY27, marking its entry into the European market. The key details are summarised below:

Aumolertinib Launch Anticipated in H2 FY27

In the oncology segment, Glenmark Pharmaceuticals has indicated that the initial launch of Aumolertinib is anticipated in the second half of FY27. This represents a notable pipeline milestone for the company's oncology portfolio. The key details are outlined below:

Strategic Outlook

Glenmark Pharmaceuticals' FY27 agenda encompasses growth across multiple therapeutic areas, with US respiratory launches including Fluticasone MDI 44, the EU entry of Winlevi®, the anticipated rollout of Aumolertinib, and continued momentum from Ryaltris forming the core pillars of its near-term strategy. These developments collectively reflect the company's efforts to advance its product pipeline and broaden its geographic and therapeutic reach during the fiscal year.

*Source: *